2 Beaten-Down Stocks That Could Sink Even More in 2026

2026-01-21 22:50:00 ET

The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make them attractive at current levels if there are good reasons to think they will bounce back.

However, that's hardly the case. Sarepta Therapeutics and Teladoc Health both face significant challenges that might, once again, lead to poor performance in 2026. Here's why neither stock is worth investing in right now.

Image source: Getty Images.

Continue reading